Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 252 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Japanese Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00912353
View directory record Official record
Conditions
Healthy
Interventions
AZD7268, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Gelndale, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

NCT01520987
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIA 9-1067, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

NCT02104765
View directory record Official record
Conditions
Migraine Disorders
Interventions
LY2951742, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

NCT01815827
View directory record Official record
Conditions
Healthy Volunteer
Interventions
inclacumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Japanese Pharmacokinetic Bridging Study for CC-93538

NCT04096105
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

NCT04079101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB104, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

NCT06444191
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rilzabrutinib
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

NCT06715670
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Zibotentan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 4, 2026, 7:10 PM EDT
Completed No phase listed Observational

A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT06699914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

NCT06502379
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8965, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 4, 2026, 7:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

NCT05197426
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Oral Azacitidine, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

NCT06315335
View directory record Official record
Conditions
Healthy Participants
Interventions
UCB9741, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

NCT00983099
View directory record Official record
Conditions
Healthy
Interventions
Neramexane
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
20 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

NCT02039076
View directory record Official record
Conditions
Thrombocytopenia
Interventions
avatrombopag
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975
View directory record Official record
Conditions
COPD
Interventions
PT010 Dose 1, PT010 Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 4, 2026, 7:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

NCT07525947
View directory record Official record
Conditions
Healthy Volunteers (HV)
Interventions
JADE101
Drug
Lead sponsor
Jade Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

NCT03224260
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986177, Matched Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

NCT01081821
View directory record Official record
Conditions
Healthy
Interventions
single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

NCT03250598
View directory record Official record
Conditions
Healthy, Japanese, Non-Asian
Interventions
AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 4, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhNGF 20μg/mL, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 4, 2026, 7:10 PM EDT